Lonza offloads specialty ingredients unit in $4.7B sale to Bain Capital, Cinven in consolidation around biopharma
With the biopharma CDMO market on a yearslong upswing, giant Lonza has looked to rework the game plan to keep its golden goose productive. After tinkering with its capsule offerings, the Swiss manufacturer will now offload an ingredients unit that was once one of its business pillars.
Lonza will sell its specialty ingredients business to Bain Capital and UK private equity firm Cinven for $4.67 billion as the contract manufacturer continues to consolidate its business around biopharma work and capsules, the company said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.